Patents/Inventors

Michel Sadelain

New York, NYUS13 patents

14 Patents

US126068482026
Globin Gene Therapy for Treating Hemoglobinopathies
MEMORIAL SLOAN-KETTERING CANCER CENTER
0 cites
US123457122025
Cancer Antigen Targets and Uses Thereof
MEMORIAL SLOAN-KETTERING CANCER CENTER
0 cites
US123311292025
Chimeric Receptors Targeting ADGRE2 And/or CLEC12A and Uses Thereof
MILLENNIUM PHARMACEUTICALS, Inc.
0 cites
US122758022025
Compositions and Methods for Immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER
0 cites
US122632202025
Compositions and Methods for Immunotherapy
MEMORIAL SLOAN-KETTERING CANCER CENTER
0 cites
US122593902025
Cancer Antigen Targets and Uses Thereof
MEMORIAL SLOAN-KETTERING CANCER CENTER
0 cites
US121395242024
Immune Cell Compositions and Methods of Use
Memorial Sloan Kettering Cancer Center
0 cites
US120362442024
Cells Comprising Non-hla Restricted T Cell Receptors
MEMORIAL SLOAN-KETTERING CANCER CENTER
0 cites
US120180772024
Methods of Treatments Using Antigen-binding Proteins Targeting CD56
THE U.S.A. AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
0 cites
US119326902024
Enhanced Chimeric Antigen Receptors and Uses Thereof
MEMORIAL SLOAN-KETTERING CANCER CENTER
0 cites
US117536542023
Globin Gene Therapy for Treating Hemoglobinopathies
MEMORIAL SLOAN-KETTERING CANCER CENTER
0 cites
US117175792023
Globin Gene Therapy for Treating Hemoglobinopathies
UNIVERSITY OF WASHINGTON
0 cites
US117124692023
Compositions and Methods for Immunotherapy
MEMORIAL SLOAN-KETTERING CANCER CENTER
0 cites
US117024722023
Method of Reducing Mesothelin-expressing Tumor Burden by Administration of T Cells Comprising Mesothelin-targeted Chimeric Antigen Receptors
THE U.S.A. AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
0 cites